Fmr LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 48.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,530,755 shares of the company’s stock after purchasing an additional 8,319,805 shares during the period. Fmr LLC owned approximately 0.82% of AstraZeneca worth $1,686,816,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of AZN. Better Money Decisions LLC purchased a new position in AstraZeneca during the 2nd quarter valued at about $25,000. DB Wealth Management Group LLC acquired a new position in shares of AstraZeneca during the 1st quarter worth approximately $26,000. Parkside Financial Bank & Trust lifted its stake in AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after buying an additional 390 shares in the last quarter. HHM Wealth Advisors LLC acquired a new stake in AstraZeneca during the 2nd quarter valued at $28,000. Finally, Fairfield Bush & CO. purchased a new position in AstraZeneca during the first quarter worth $28,000. 21.55% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently commented on AZN shares. AlphaValue raised AstraZeneca to a “reduce” rating in a research note on Monday, August 22nd. Argus raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, August 29th. TheStreet downgraded shares of AstraZeneca from a “b-” rating to a “c” rating in a research note on Tuesday, August 30th. Morgan Stanley downgraded AstraZeneca from an “overweight” rating to an “equal weight” rating in a report on Wednesday, September 7th. Finally, Berenberg Bank decreased their price objective on AstraZeneca from GBX 120 ($1.42) to GBX 118 ($1.40) in a report on Wednesday, October 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Hold” and an average price target of $8,264.20.
AstraZeneca Trading Up 0.2 %
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.